United Kingdom · Venture startup

Who invested in Xenetic Biosciences

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$10Mraised across 1 round since 2014, from 1 source

Latest round
Venture, $10MJan 2014
Investors
1
See who backed them

The rounds

  1. Jan 2014
    Venture$10M

    From a historical funding record

Founders and team

From Xenetic Biosciences's own website and the SEC filings it signed: 4 on the team.

  • Scott N. CullisonInterim Chief Executive Officer and Chief Financial Officer
  • James F. ParslowInterim Chief Executive Officer and Chief Financial Officer
  • Jeffrey EisenbergCEOi
  • Curtis LockshinChief Science Officeri

On the board, as filediAdam LogalAlexey VinogradovFirdaus DastoorGrigory BorisenkoJames CallawayRoger Kornberg

Everyone who backed them

Baxter VenturesCorporate VC1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Xenetic Biosciences

Who invested in Xenetic Biosciences?

Xenetic Biosciences's investors include Baxter Ventures.

How much has Xenetic Biosciences raised?

Xenetic Biosciences has raised $10M across 1 round since 2014.

When did Xenetic Biosciences last raise?

Xenetic Biosciences's most recent round was a Venture of $10M in Jan 2014.

What was Xenetic Biosciences's biggest round?

Its most recent round, $10M in Jan 2014, is also its largest on record.

Who backed Xenetic Biosciences first?

Xenetic Biosciences's first round on record, in Jan 2014, was backed by Baxter Ventures.

What stage is Xenetic Biosciences at?

Xenetic Biosciences's latest named round is a Venture, in Jan 2014.

Where is Xenetic Biosciences based?

Xenetic Biosciences is based in the United Kingdom.

Companies like Xenetic Biosciences

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.